metsera glp-1 Pfizer to Acquire Metsera, Advancing Obesity and Cardiometabolic Treatments | Albert Bourla posted on the topic China approves Pfizer GLP-1 drug

Individuals with underlying gastrointestinal conditions may experience more pronounced symptoms and should consult healthcare providers before initiating supplementation

A slight reduction in blood pressure has also been observed in SUSTAIN-6 and LEADER trials [53, 54]

According to the company, the patches are designed for daily use

However, some side effects can arise from GLP-1 agonist use

The EU5 public healthcare systems also reimburse GLP-1s, but often with prescribing restrictions such as specialist approval or use only as 3rd line treatment at the earliest, which limits penetration

Compounding allows this therapy to be tailored to specific patient needs, offering personalized dosage adjustments and alternative delivery mechanisms